September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The Therapeutic Utility of Decorin Eye Drops for the Prevention of Corneal Scarring
Author Affiliations & Notes
  • Maryam Esmaeili
    Neurotrauma , University of Birmingham , Birmingham, England, United Kingdom
  • Zubair Ahmed
    Neurotrauma , University of Birmingham , Birmingham, England, United Kingdom
  • Saaeha Rauz
    Opthalmology, University of Birmingham , Birmingham, United Kingdom
  • Liam M. Grover
    Biochemical Engineering, University of Birmingham , Birmingham, United Kingdom
  • Ann Logan
    Neurotrauma , University of Birmingham , Birmingham, England, United Kingdom
  • Footnotes
    Commercial Relationships   Maryam Esmaeili, None; Zubair Ahmed, None; Saaeha Rauz, None; Liam Grover, None; Ann Logan, None
  • Footnotes
    Support  Wellcome Trust
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1291. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Maryam Esmaeili, Zubair Ahmed, Saaeha Rauz, Liam M. Grover, Ann Logan; The Therapeutic Utility of Decorin Eye Drops for the Prevention of Corneal Scarring
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):1291.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal opacity is a leading cause of worldwide blindness. The availability of drugs to treat established corneal scars or the prevention of scar formation following trauma, is limited. We have previously shown that Decorin, a naturally occurring antagonist of TGF-beta, creates a permissive microenvironment that enables healing with reduction of pro-fibrotic cascades. In this study, we examined the use of Decorin eye drops as an early stage intervention to reduce visually significant corneal scar formation in a corneal injury animal model.

Methods : Decorin was delivered as a single 40µL drop onto the corneal surface of anaesthetised adult Sprague-Dawley rats and penetration into the cornea and aqueous humour (AqH) was assessed at 0, 30, 60 min by immunohistochemistry and ELISA, respectively. Eyedrop deliverable levels of Decorin were compared with those present endogenously in human AqH. An ex-vivo rat corneal-scarring alkali burn model was established by exposing the central cornea to filter paper saturated with 0.5M NaOH to varying time points (15, 30 and 60 s) followed by histological analysis of tissue for corneal scarring. The topical application of Decorin was evaluated.

Results : Decorin penetrated the rat cornea into the anterior segment of the eye. While Decorin levels in corneal tissue increased over time, concentrations in the AqH decreased (10 min, 12600pg/mL (±3382pg/mL (SEM); n=3) to 60 min, 4600pg/mL (±3494pg/mL (SEM); n=3)). This level was comparable to physiological concentrations of Decorin in human AqH (1904pg/mL (± 360pg/mL (SEM); n=10). Topical Decorin is able to prevent corneal scar formation in our ex vivo rat corneal-alkali injury model compared to eyes that were not treated with Decorin.

Conclusions : Topical application of Decorin is effective in reducing corneal scar formation during acute alkali injury and is likely to be therapeutically useful in the prevention of corneal scarring. Anterior-segment penetration of Decorin may afford a novel anti-fibrotic strategy for intraocular scarring processes.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×